Immunogenicity to biologic drugs in IBD (IMGEN)

Immunogenicity to biologic drugs in IBD (IMGEN) is a new study added to Predicting Drug Side Effects in Gastroenterology (PRED4) at the beginning of 2018:


The inclusion criteria are as follows:

  • Patient currently aged ≥ 6 years
  • History of ulcerative colitis (UC) or Crohn’s disease (CD)
  • Biologic drug and antibody concentrations previously measured in Exeter, or patient prepared prepared to give sample for this purpose.
  • At time of drug and antibody measurement:
  1.          Biologic treatment duration >24 months, or
  2.          Treatment duration ≤ 24 months with episode of loss of response requiring escalation of immunomodulatory, steroid or biologic therapy, or withdrawal of current biologic therapy.
  • Drug and antibody level taken at one of the following time points:
  1.          For patients still on drug: within 72 hours prior to the next dose of drug (trough level), or
  2.          For patients who have stopped drug: no sooner than 72 hours before and no later than one month after their next dose would have been due and before starting next biologic
  • Patient has not participated in PANTS study.
  • Patient is able to provide informed consent.



You can also log on to the link and enter the information here. You will need to request a user name and password from Claire Bewshea, email